Cat. No. 3436
Biological ActivityPotent neuropeptide Y (NPY) Y5 receptor agonist (pEC50 values are 7.82, 6.28, 6.44 and > 6 at rat Y5, Y4, Y1 and Y2 receptors respectively) that displays > 26-fold, > 1000-fold and > 1000-fold selectivity over Y1, Y2 and Y4 receptors respectively. Induces hyperphagia, body weight gain, adiposity, hypercholesterolemia, hyperinsulinemia and hyperleptinemia in vivo. Orally active.
(Modifications: Trp-34 = D-Trp, Tyr-36 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Beck et al (2007) Responsiveness of obese Zucker rats to [D-Trp34]-NPY supports the targeting of Y5 receptor for obesity treatment. Nutr.Neurosci. 10 211. PMID: 18284029.
Mashiko et al (2003) Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp34NPY. Endocrinology 144 1793. PMID: 12697685.
Parker et al (2000) [D-Trp34] neuropeptide Y is a potent and selective neuropeptide Y Y5 receptor agonist with dramatic effects on food intake. Peptides 21 393. PMID: 10793222.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses [D-Trp34]-Neuropeptide Y from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: [D-Trp34]-Neuropeptide Y, supplier, Potent, NPY, Y5, agonists, orexigenic, Neuropeptide, Y, Receptors, [D-Trp34]-NeuropeptideY, neuropeptides, Tocris Bioscience, NPY Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonist
April 1 - 5, 2017
Washington, D.C., USA